Maven Securities’s Capricor Therapeutics CAPR Stock Holding History

Maven Securities’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-150,000	Closed	-$2.07M	–	806
2024 Q4	$2.07M	Buy	+150,000	New	+$2.63M	0.05%	280

Other funds holding CAPR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Maven Securities's CAPR Position: Q1 2025 in Review

Maven Securities sold out of Capricor Therapeutics (CAPR) in Q1 2025, closing a stake of 150,000 shares — an estimated $2.07M sold.

Maven Securities first reported a position in CAPR in Q4 2024 and held it in 1 quarter. The position peaked at $2.07M in Q4 2024. 120 funds tracked by Wall St. Rank hold CAPR as of Q1 2025.

Maven Securities reported no remaining Capricor Therapeutics position as of Q1 2025 after selling out during the quarter.
Maven Securities sold 150,000 Capricor Therapeutics shares in Q1 2025, an estimated $2.07M.
Maven Securities first reported a position in Capricor Therapeutics in Q4 2024 and held it in 1 quarter.
Maven Securities's Capricor Therapeutics position peaked at $2.07M in Q4 2024.
120 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2025.

Based on Maven Securities's 13F filing for Q1 2025, filed 14 May 2025.